James A. Fletcher M.B.B.S. , William J. Mullally MBBCh BAO , Rahul Ladwa MPhil , Kenneth J. O’Byrne MD
{"title":"阿来替尼诱发肺炎后的罗拉替尼:病例报告","authors":"James A. Fletcher M.B.B.S. , William J. Mullally MBBCh BAO , Rahul Ladwa MPhil , Kenneth J. O’Byrne MD","doi":"10.1016/j.jtocrr.2023.100591","DOIUrl":null,"url":null,"abstract":"<div><p><em>ALK</em> gene rearrangements are detected in approximately 3% to 5% of NSCLC. <em>ALK</em> tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in <em>ALK</em>-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after <em>ALK</em> tyrosine kinase inhibitors–induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001340/pdfft?md5=bd98224b5ca00552f89132e9ae085664&pid=1-s2.0-S2666364323001340-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report\",\"authors\":\"James A. Fletcher M.B.B.S. , William J. Mullally MBBCh BAO , Rahul Ladwa MPhil , Kenneth J. O’Byrne MD\",\"doi\":\"10.1016/j.jtocrr.2023.100591\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><em>ALK</em> gene rearrangements are detected in approximately 3% to 5% of NSCLC. <em>ALK</em> tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in <em>ALK</em>-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after <em>ALK</em> tyrosine kinase inhibitors–induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001340/pdfft?md5=bd98224b5ca00552f89132e9ae085664&pid=1-s2.0-S2666364323001340-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001340\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report
ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after ALK tyrosine kinase inhibitors–induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.